MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients

References

• Agaugue S, Marcenaro E, Ferranti B, Moretta L, Moretta A. 2008. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells. Blood 112:1776–1783.
   PubMed Web of Science ®Google Scholar
• Bartel DP. 2009. MicroRNAs: target recognition and regulatory functions. Cell 136:215–233.
   PubMed Web of Science ®Google Scholar
• Baserga R. 1995. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 55:249–252.
   PubMed Web of Science ®Google Scholar
• Bezman NA, Cedars E, Steiner DF, Blelloch R, Hesslein DG, Lanier LL. 2010. Distinct requirements of microRNAs in NK cell activation, survival, and function. J Immunol 185:3835–3846.
   PubMed Web of Science ®Google Scholar
• Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, et al. 2006. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol 176:5108–5116.
   PubMed Web of Science ®Google Scholar
• Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, et al. 2008. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129:428–437.
   PubMed Web of Science ®Google Scholar
• Di Santo JP. 2008. Natural killer cells: diversity in search of a niche. Nat Immunol 9:473–475.
   PubMed Web of Science ®Google Scholar
• El Tayebi HM, Hosny KA, Esmat G, Breuhahn K, Abdelaziz AI. 2012. miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma. FEBS Lett 586:3309–3316.
   PubMed Web of Science ®Google Scholar
• El Tayebi HM. 2014. Transcriptional activation of IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncol Lett 10:3206–3212.
   Google Scholar
• Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. 2003. Biology and clinical impact of human natural killer cells. Int J Hematol 78:7–17.
   PubMed Web of Science ®Google Scholar
• Gao H, Deng H, Xu H, Yang Q, Zhou Y, Zhang J, Zhao D, Liu F. 2016. MicroRNA-223 promotes mast cell apoptosis by targeting the insulin-like growth factor 1 receptor. Exp Ther Med 11:2171–2176.
   PubMed Web of Science ®Google Scholar
• Gao J, Duan Z, Zhang L, Huang X, Long L, Tu J, Liang H, et al. 2016. Failure recovery of circulating NKG2D + CD56dimNK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. Oncoimmunology 5:e1048061.
   PubMed Web of Science ®Google Scholar
• Ge YY, Shi Q, Zheng ZY, Gong J, Zeng C, Yang J, Zhuang SM. 2014. MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R. Oncotarget 5:6218–6228.
   PubMed Web of Science ®Google Scholar
• Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, Walzer T. 2007. The trafficking of natural killer cells. Immunol Rev 220:169–182.
   PubMed Web of Science ®Google Scholar
• Hayakawa Y, Screpanti V, Yagita H, Grandien A, Ljunggren HG, Smyth MJ, Chambers BJ. 2004. NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J Immunol 172:123–129.
   PubMed Web of Science ®Google Scholar
• Ishiyama K, Ohdan H, Ohira M, Mitsuta H, Arihiro K, Asahara T. 2006. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 43:362–372.
   PubMed Web of Science ®Google Scholar
• Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G, Sykora KW, Schmidt RE. 2001. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 31:3121–3127.
   PubMed Web of Science ®Google Scholar
• Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE. 1992. CD16- CD56+ natural killer cells after bone marrow transplantation. Blood 79:3239–3244.
   PubMed Web of Science ®Google Scholar
• Jamitzky S, Krueger AC, Janneschuetz S, Piepke S, Kailayangiri S, Spurny C, Rossig C, Altvater B. 2015. Insulin-like growth factor-1 receptor (IGF-1R) inhibition promotes expansion of human NK cells which maintain their potent antitumor activity against Ewing sarcoma cells. Pediatr Blood Cancer 62:1979–1985.
   PubMed Web of Science ®Google Scholar
• Ji T, Li G, Chen J, Zhao J, Li X, Lin H, Cai X, Cang Y. 2016. Distinct role of interleukin-6 and tumor necrosis factor receptor-1 in oval cell- mediated liver regeneration and inflammation-associated hepatocarcinogenesis. Oncotarget 7:66635–66646.
   PubMed Web of Science ®Google Scholar
• Jiang W, Zhang C, Tian Z, Zhang J. 2014. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo. Immunobiology 219:547–553.
   PubMed Web of Science ®Google Scholar
• Jost S, Altfeld M. 2013. Control of human viral infections by natural killer cells. Annu Rev Immunol 31:163–194.
   PubMed Web of Science ®Google Scholar
• Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, Heijnen CJ, Zegers BJ. 1992. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinology 131:2244–2250.
   PubMed Web of Science ®Google Scholar
• Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J. 2015. Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6:13835–13843.
   PubMed Web of Science ®Google Scholar
• Lund P, Schubert D, Niketeghad F, Schirmacher P. 2004. Autocrine inhibition of chemotherapy response in human liver tumor cells by insulin-like growth factor-II. Cancer Lett 206:85–96.
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. 2007. AKT/PKB signaling: navigating downstream. Cell 129:1261–1274.
   PubMed Web of Science ®Google Scholar
• Martin DC, Fowlkes JL, Babic B, Khokha R. 1999. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1. J Cell Biol 146:881–892.
   PubMed Web of Science ®Google Scholar
• Nagler A, Lanier LL, Cwirla S, Phillips JH. 1989. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 143:3183–3191.
   PubMed Web of Science ®Google Scholar
• Ni F, Sun R, Fu B, Wang F, Guo C, Tian Z, Wei H. 2013. IGF-1 promotes the development and cytotoxic activity of human NK cells. Nat Commun 4:1479.
   PubMed Web of Science ®Google Scholar
• Pollak MN, Schernhammer ES, Hankinson SE. 2004. Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–518.
   PubMed Web of Science ®Google Scholar
• Su R, Dong Zou L, Zhao D, Ren H, Li Y, Yi F, Li P, et al. 2016. microRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. Oncogene 35:6001–6014.
   PubMed Web of Science ®Google Scholar
• Thomas MF, Abdul-Wajid S, Panduro M, Babiarz JE, Rajaram M, Woodruff P, Lanier LL, et al. 2012. Eri1 regulates microRNA homeostasis and mouse lymphocyte development and antiviral function. Blood 120:130–142.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. 1989. Biology of natural killer cells. Adv Immunol 47:187–376.
   PubMed Web of Science ®Google Scholar
• Xu Y, Huang J, Ma L, Shan J, Shen J, Yang Z, Liu L, et al. 2016. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways. Cancer Lett 371:171–181.
   PubMed Web of Science ®Google Scholar
• Yadav A, Kalita A, Dhillon S, Banerjee K. 2005. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J Biol Chem 280:31830–31840.
   PubMed Web of Science ®Google Scholar
• Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, Lu H, et al. 2003. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J Clin Invest 111:265–273.
   PubMed Web of Science ®Google Scholar
• Youness RA, Rahmoon MA, Assal RA, Gomaa AI, Hamza MT, Waked I, El Tayebi HM, Abdelaziz AI. 2016. Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. Growth Factors 34:128–140.
   PubMed Web of Science ®Google Scholar
• Zhang QF, Yin W, Xia WY, Yi YY, He Q, Wang F, Ren XH, Zhang DZ. 2016. Liver-infiltrating CD11b-CD27- NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression. Cell Mol Immunol. Epub ahead of print. doi: 10.1038/cmi.2016.28
   Google Scholar
• Zhang W, Liu K, Liu S, Ji B, Wang Y, Liu Y. 2015. MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. Tumour Biol 36:9779–9788.
   PubMed Web of Science ®Google Scholar